What's In Store For Merck Stock In 2025?
Portfolio Pulse from
Merck stock (NYSE: MRK) underperformed in 2024, losing about 10% while the S&P 500 gained 23%. In contrast, Eli Lilly and AbbVie saw stock increases of 31% and 15%, respectively.
January 17, 2025 | 3:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Merck's stock underperformed in 2024, losing 10% compared to the S&P 500's 23% gain. This underperformance is notable against peers like Eli Lilly and AbbVie.
Merck's stock performance in 2024 was notably poor, losing 10% while the broader market and peers like Eli Lilly and AbbVie saw gains. This suggests potential investor concerns or challenges specific to Merck.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100